{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:45:43Z","timestamp":1773290743997,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (CMV), a common post\u2010transplant infection, is associated with increased healthcare resource utilization. In the Phase 3 SOLSTICE trial, maribavir was superior to investigator\u2010assigned therapy (IAT; valganciclovir\/ganciclovir, foscarnet, and cidofovir) for CMV viremia clearance at Week 8 in transplant recipients with confirmed refractory CMV infection with\/without resistance. This exploratory analysis evaluated hospital admissions of patients during the SOLSTICE trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were randomized to maribavir (400\u00a0mg twice daily) or IAT for an 8\u2010week treatment phase with a 12\u2010week follow\u2010up. After \u22653 weeks of treatment, patients on IAT who met pre\u2010specified criteria could enter a maribavir rescue arm (8\u2010week maribavir treatment, 12\u2010week follow\u2010up). Adjusted hospitalization rates and length of hospital stay (LOS) were estimated using negative binomial models adjusting for the time in the relevant study phase. Subgroup analysis for the maribavir rescue arm was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 352 patients were randomized (maribavir: 235; IAT: 117); 22 entered the maribavir rescue arm. After adjusting for treatment exposure, patients on maribavir had a 34.8% reduction in hospitalization rate and 53.8% reduced LOS (days\/person\/year) versus IAT during the treatment phase. No significant differences between treatments were observed during the follow\u2010up phase, although in both arms, hospitalization rates were lower than in the treatment phase. In the maribavir rescue arm, hospitalizations were 60.6% lower on\/after maribavir rescue versus pre\u2010rescue treatment (<jats:italic>p<\/jats:italic> = 0.008).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients requiring post\u2010transplant CMV treatment, hospitalization rate and LOS were lower for maribavir than IAT, and hospitalization rates were lower on\/after maribavir rescue than pre\u2010rescue. Reducing hospitalizations can alleviate the burden on patients and healthcare systems.\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid14064-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.14064","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:44:13Z","timestamp":1683549853000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Healthcare resource utilization of maribavir versus investigator\u2010assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-865X","authenticated-orcid":false,"given":"Ishan","family":"Hirji","sequence":"first","affiliation":[{"name":"Global Evidence &amp; Outcomes, Research and Development Takeda Development Center Americas, Inc.  Lexington Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[{"name":"Patient\u2010Centered Outcomes Adelphi Values  Bollington UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Moreno\u2010Koehler","sequence":"additional","affiliation":[{"name":"Patient\u2010Centered Outcomes Adelphi Values  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Sundberg","sequence":"additional","affiliation":[{"name":"Clinical Science, Research and Development Takeda Development Center Americas, Inc.  Lexington Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(07)09"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12686"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001418"},{"key":"e_1_2_10_6_1","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection","author":"Mehta Steinke SA","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1174571"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13058"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2046388"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.615"},{"issue":"10","key":"e_1_2_10_11_1","first-page":"690","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post\u2010transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery RK","year":"2021","journal-title":"Clin Infect Dis"},{"key":"e_1_2_10_12_1","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA).Welcome to MedDRA. 2023; Accessed December 20 2022https:\/\/www.meddra.org\/"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.14064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T19:12:01Z","timestamp":1692472321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.14064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/tid.14064"],"URL":"https:\/\/doi.org\/10.1111\/tid.14064","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"2022-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14064"}}